CA2769541A1 - Compounds for treatment of inflammation - Google Patents

Compounds for treatment of inflammation Download PDF

Info

Publication number
CA2769541A1
CA2769541A1 CA2769541A CA2769541A CA2769541A1 CA 2769541 A1 CA2769541 A1 CA 2769541A1 CA 2769541 A CA2769541 A CA 2769541A CA 2769541 A CA2769541 A CA 2769541A CA 2769541 A1 CA2769541 A1 CA 2769541A1
Authority
CA
Canada
Prior art keywords
inflammation
treatment
pharmaceutical composition
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2769541A
Other languages
English (en)
French (fr)
Inventor
Niklas Palmqvist
Anders Sjoedin
Christina Wenglen
Christofer Flood
Lennart Lundberg
Elisabeth Seifert
Per Lek
Arne Boman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anamar AB
Original Assignee
Anamar AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0913427A external-priority patent/GB0913427D0/en
Priority claimed from GBGB1005495.5A external-priority patent/GB201005495D0/en
Priority claimed from GBGB1010671.4A external-priority patent/GB201010671D0/en
Application filed by Anamar AB filed Critical Anamar AB
Publication of CA2769541A1 publication Critical patent/CA2769541A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2769541A 2009-07-31 2010-07-30 Compounds for treatment of inflammation Abandoned CA2769541A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0913427.1 2009-07-31
GB0913427A GB0913427D0 (en) 2009-07-31 2009-07-31 Compounds for treatment of imflammation
GB1005495.5 2010-03-31
GBGB1005495.5A GB201005495D0 (en) 2010-03-31 2010-03-31 Compounds for treatment of inflammation
GB1010671.4 2010-06-24
GBGB1010671.4A GB201010671D0 (en) 2010-06-24 2010-06-24 Compounds for treatment of inflammation
PCT/GB2010/001457 WO2011012868A1 (en) 2009-07-31 2010-07-30 Compounds for treatment of inflammation

Publications (1)

Publication Number Publication Date
CA2769541A1 true CA2769541A1 (en) 2011-02-03

Family

ID=42799430

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2769541A Abandoned CA2769541A1 (en) 2009-07-31 2010-07-30 Compounds for treatment of inflammation

Country Status (13)

Country Link
US (1) US20120190751A1 (OSRAM)
EP (1) EP2470270A1 (OSRAM)
JP (1) JP2013500957A (OSRAM)
CN (1) CN102573993A (OSRAM)
AU (1) AU2010277356A1 (OSRAM)
BR (1) BR112012002267A2 (OSRAM)
CA (1) CA2769541A1 (OSRAM)
GB (1) GB2473095A (OSRAM)
IN (1) IN2012DN00928A (OSRAM)
MX (1) MX2012001144A (OSRAM)
NZ (1) NZ598124A (OSRAM)
RU (1) RU2012106467A (OSRAM)
WO (1) WO2011012868A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3109237A1 (en) * 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
CN105561313B (zh) * 2016-01-25 2018-12-25 北京大学 降低5-ht2br含量和抑制其活性的物质在制备治疗和预防动脉粥样硬化产品中的应用
US11208475B1 (en) * 2018-01-30 2021-12-28 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
JP2021529729A (ja) * 2018-05-09 2021-11-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｉ型ｉｆｎ依存性病態を処置するためのグアナベンズ又はその誘導体の使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520032B1 (en) * 1990-03-16 1998-09-16 Beth Israel Hospital Association Use of spiperone as an immunosuppressant and anti-inflammatory agent
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
EP0711553A1 (en) * 1994-08-09 1996-05-15 Mario Cagnoni Use of the Melatonin in the traetment of the articular symptoms of trheumatoid arthritis
AU7802700A (en) * 1999-10-06 2001-05-10 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
GB0019357D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US7060711B2 (en) * 2001-10-25 2006-06-13 Biofrontera Bioscience Gmbh Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist
AU2004276812A1 (en) * 2003-09-25 2005-04-07 Acadia Pharmaceuticals Inc. Treating neuropathic pain with neuropeptide FF receptor 2 agonists
GB0623381D0 (en) * 2006-11-23 2007-01-03 Acure Pharma Ab Use of a compound as VEGF inhibitor
GB0701170D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
GB0715048D0 (en) * 2007-08-02 2007-09-12 Glaxo Group Ltd Novel compounds
WO2010109192A1 (en) * 2009-03-24 2010-09-30 Anamar Ab Metabolic profiles

Also Published As

Publication number Publication date
WO2011012868A1 (en) 2011-02-03
IN2012DN00928A (OSRAM) 2015-04-03
RU2012106467A (ru) 2013-09-10
MX2012001144A (es) 2012-05-08
GB2473095A (en) 2011-03-02
CN102573993A (zh) 2012-07-11
AU2010277356A1 (en) 2012-03-08
BR112012002267A2 (pt) 2016-11-08
JP2013500957A (ja) 2013-01-10
GB201012926D0 (en) 2010-09-15
NZ598124A (en) 2014-01-31
EP2470270A1 (en) 2012-07-04
US20120190751A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
US10398679B2 (en) Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors
CN101801362B (zh) 用于治疗病症的方法和组合物
JP5652417B2 (ja) 三環式化合物およびその用途
JPWO2005040135A1 (ja) 抗ストレス薬およびその医薬用途
EP1438973A1 (en) Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
EP3215152A1 (en) SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP)
JPWO2004014428A1 (ja) 腸疾患および内臓痛の治療薬
JP2017014224A (ja) 帯状疱疹関連痛の急性期疼痛の予防又は治療剤
KR101747486B1 (ko) 동통 치료제
CA2769541A1 (en) Compounds for treatment of inflammation
JPWO2005080322A1 (ja) フルオレン誘導体
JPH06506192A (ja) 阻害剤
EP1716867A1 (en) Preventives for migraine
KR20080044273A (ko) 아실구아니딘 유도체 또는 그의 염
JP4998258B2 (ja) 過敏性腸症候群の治療薬
JP2005314347A (ja) 疼痛抑制剤
CN113861176A (zh) 一种黄病毒抑制剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150625

FZDE Discontinued

Effective date: 20170801